The Global Acute Ischemic Stroke (AIS) Market primarily deals with providing diagnostic and therapeutic solutions for patients suffering from acute ischemic stroke. AIS occurs due to blockage of blood vessels supplying blood to the brain, which can be caused by thrombosis or embolism that restricts blood flow. The market offers diversified products such as diagnostic imaging devices, thrombolytic drugs, antihypertensive drugs, anticoagulants and others. The early diagnosis through CT or MRI scans followed by appropriate thrombolytic or antithrombotic therapies within the therapeutic window plays a vital role in reducing mortality and neurological deficits associated with the condition.

The Global AIS Market is estimated to be valued at US$ 10612.22 Bn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031.

The Acute Ischemic Stroke Market Growth can be highly attributed to rising geriatric population globally. As age is the primary risk factor for AIS, increased life expectancy has augmented the number of elderly population liable to develop the condition. As per WHO, there were approximately 703 million people aged 65 years or over in 2019 and their numbers are projected to cross 1.5 billion by 2050. This widening geriatric demographic presents huge patient pool opportunity for AIS market.

The current geopolitical tensions and economic uncertainties across several regions are anticipated to impact the growth of the AIS market during the forecast period. The ongoing Russia-Ukraine war and sanctions imposed by Western nations have disrupted the global supply chains and economies of many Eastern European countries. This has constrained the healthcare spending and prioritization of non-communicable diseases in these regions. At the same time, the increasing prevalence of lifestyle diseases and growing geriatric population continue to drive the demand for effective AIS treatments. The market players need to closely monitor the geopolitical changes and Devise contingency plans to minimize supply disruptions. They also need to consider expanding their manufacturing footprints across multiple regions and countries to reduce overdependence on single markets. Partnering with local players can help gain better access to emerging patient pools in developing Asian and Latin American countries.

The North American region currently holds the largest share in the global AIS market in terms of value, owing to the well-established healthcare systems, high patient awareness levels, and sizable research and development investments by leading pharmaceutical companies in the region. However, the growing healthcare expenditure and rapidly expanding patient population make the Asian markets an attractive avenue for future growth. Countries like China and India are expected to contribute significantly to the AIS market growth during the forecast period due to rising incidences of stroke, increasing penetration of advanced treatment options, and availability of low-cost generics.